Acute Leukemia

Introduction

A diagnosis of acute leukemia or being told that tests point strongly toward it is one of the most disorienting moments a person can face. Things often move quickly: blood tests, a bone marrow biopsy, conversations about chemotherapy, and decisions that need to be made within days rather than weeks. If you are reading this, you or someone close to you is likely already in that process.

This guide is written to help you understand what acute leukemia is, how doctors classify it, what the main treatment phases look like, when a stem cell transplant may be part of the plan, and what life looks like during and after treatment. It is not a substitute for the conversations you are having with your hematologist, but it can help you walk into those conversations with a clearer picture and better questions.

Acute leukemia is serious, but it is also one of the cancers where treatment has changed the most in recent decades. Many patients reach remission, and a significant number go on to long-term, disease-free lives.

What Is Acute Leukemia?

Leukemia is a cancer of the blood and bone marrow. The bone marrow is the soft tissue inside large bones where blood cells are made. Normally, the marrow produces three main types of mature blood cells: red blood cells (which carry oxygen), platelets (which help blood clot), and white blood cells (which fight infection).

In acute leukemia, the marrow starts producing large numbers of abnormal, immature white blood cells called blasts. These blasts do not mature into functioning cells, and they multiply quickly. As they fill up the marrow, they crowd out the production of healthy red cells, platelets, and normal white cells. This is why people with acute leukemia often feel tired (low red cells), bruise or bleed easily (low platelets), and get infections (low functional white cells), even though their total white cell count on a blood test may be high.

The word acute refers to how quickly the disease develops. Without treatment, acute leukemia can progress over weeks. This is different from chronic leukemia, which develops gradually over months or years and is sometimes monitored without immediate treatment.

Types of Acute Leukemia

Doctors divide acute leukemia mainly by the type of white blood cell that has become cancerous.

Acute Myeloid Leukemia (AML)

AML starts in myeloid cells — the marrow cells that normally develop into red blood cells, platelets, and several types of white cells. AML is the more common form in adults, particularly in people over 60, but it can occur at any age, including in children.

AML is itself a family of diseases. Doctors classify it further using genetic and molecular tests on the leukemia cells. Specific mutations and chromosome changes (such as FLT3, NPM1, IDH1/2, and others) help predict how the leukemia is likely to behave and which drugs may work best. The European LeukemiaNet (ELN) framework and NCCN guidelines are widely used to place patients into favourable, intermediate, or adverse risk groups, which then guides treatment intensity.

Acute Lymphoblastic Leukemia (ALL)

ALL starts in lymphoid cells, the marrow cells that normally develop into lymphocytes (B cells and T cells, the main cells of the immune system). ALL is the most common cancer in children, but it also affects adults.

ALL is divided into B-cell ALL (more common) and T-cell ALL. Subtypes are also defined by specific genetic changes — for example, the Philadelphia chromosome (BCR-ABL1) is an important finding because it opens the door to targeted treatment with drugs called tyrosine kinase inhibitors.

Other and mixed forms

A small number of acute leukemias do not fit cleanly into AML or ALL and are classified as mixed phenotype acute leukemia (MPAL) or acute leukemia of ambiguous lineage. These require specialist evaluation, as treatment is individualised.

The distinction between AML and ALL is critical because the two are treated with different chemotherapy regimens. This is why bone marrow testing, immunophenotyping, and molecular tests are done at the very beginning — before treatment starts — whenever possible.

Causes and Risk Factors

In most people with acute leukemia, no single clear cause is identified. The disease arises from changes (mutations) in the DNA of blood-forming cells. Some of these mutations are present at birth, but most develop over a person’s lifetime and are not inherited.

Known factors that can increase risk include:

• Previous cancer treatment — certain chemotherapy drugs and radiation therapy given for other cancers can, years later, lead to a form sometimes called therapy-related AML.
• Prior blood disorders — conditions such as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms can evolve into AML.
• Genetic syndromes — Down syndrome, Fanconi anaemia, Li-Fraumeni syndrome, and others carry a higher risk, particularly in children.
• High-dose radiation exposure — for example, in survivors of nuclear accidents or major radiation events.
• Long-term exposure to benzene and certain industrial chemicals.
• Smoking — an established risk factor for AML in adults.
• Older age — AML risk rises substantially after age 60.

Acute leukemia is not contagious and cannot be passed from one person to another. For most patients, no specific cause can be pinned down, and it is important to understand that the disease is not the result of something you did or did not do.

Signs and Symptoms

If you are reading this after a diagnosis, you may already recognise many of the symptoms below from the weeks leading up to it. Understanding them can also help you notice changes during treatment or watch for signs of relapse later.

Because acute leukemia interferes with normal blood production, most symptoms come from low blood counts and from the leukemia cells themselves:

• From low red blood cells (anaemia): fatigue, weakness, pale skin, shortness of breath on light activity, dizziness, rapid heartbeat.
• From low platelets: easy bruising, small red or purple spots on the skin (petechiae), nosebleeds, bleeding gums, heavy menstrual bleeding.
• From low functional white cells: frequent or unusual infections, persistent fevers, slow-healing wounds.
• From leukemia cells building up: bone or joint pain, abdominal fullness from an enlarged spleen or liver, swollen lymph nodes, headaches, and occasionally skin changes.
• General: night sweats, unexplained weight loss, loss of appetite.

In children, parents may notice unusual tiredness, frequent infections, limping or refusing to walk because of bone pain, persistent low-grade fever, or unexplained bruises.

During and after treatment, similar symptoms returning — especially new bruising, persistent fevers, or sudden fatigue — should be reported to your treatment team promptly.

Diagnosis

If acute leukemia is suspected, diagnosis usually moves quickly, often within a few days. The goal is to confirm the disease, identify whether it is AML or ALL, and characterise the specific subtype so that treatment can be matched to it.

Blood tests

A complete blood count (CBC) is usually the first abnormal test. It often shows low red cells, low platelets, and either high or low white cells, often with abnormal-looking cells. A peripheral blood smear, where a drop of blood is examined under a microscope, can identify blast cells circulating in the bloodstream.

Bone marrow tests

A bone marrow aspiration and biopsy is the central test. A needle is used to take a small sample of marrow, usually from the back of the hip bone, under local anaesthesia. The procedure is uncomfortable but brief. The sample allows pathologists to:

• Count the percentage of blast cells — usually 20% or more confirms acute leukemia.
• Perform immunophenotyping (flow cytometry), which uses markers on the cell surface to distinguish AML from ALL and identify subtypes.
• Perform cytogenetic analysis to look at chromosomes inside the leukemia cells.
• Perform molecular testing to look for specific mutations (such as FLT3, NPM1, IDH1, IDH2 in AML, or BCR-ABL1 in ALL) that influence prognosis and treatment.

Additional tests

• Lumbar puncture (spinal tap) — particularly in ALL, to check whether leukemia cells are present in the fluid around the brain and spinal cord (the central nervous system).
• Imaging — chest X-ray, ultrasound, or CT scans may be used to look for enlarged lymph nodes, spleen, or liver.
• Heart and lung tests — such as echocardiogram and pulmonary function tests, to check that organs can tolerate intensive treatment.
• Infection screening — for hepatitis, HIV, and other infections that affect treatment planning.

Together, these tests give your hematology team the information needed to define your specific type and risk group, which guides every later decision.

Treatment and Management

Treatment for acute leukemia is intensive and is usually given in a hospital, particularly during the early phase. The exact plan depends on whether you have AML or ALL, the genetic features of the leukemia, your age, fitness, and other health conditions. Major guidelines from NCCN, ELN, and ESMO describe broadly similar frameworks, with treatment delivered in phases.

Phase 1: Induction

The aim of induction therapy is to bring the leukemia into remission — that is, to reduce blast cells to undetectable levels by standard tests and to restore normal blood counts.

For AML, induction is typically a combination of intensive chemotherapy given over several days, often referred to as “7+3” (seven days of one drug plus three days of another). For specific subtypes, such as acute promyelocytic leukemia (APL), the regimen is different and includes drugs called all-trans retinoic acid (ATRA) and arsenic trioxide, which have transformed outcomes in that subtype.

For ALL, induction usually combines several chemotherapy drugs given over four to six weeks, along with steroids. Treatment to protect the central nervous system — usually chemotherapy injected into the spinal fluid — is started early.

Induction often requires four to six weeks in hospital, including time for blood counts to recover. During this period, supportive care — blood and platelet transfusions, antibiotics, antifungals, and careful infection prevention — is as important as the chemotherapy itself.

Phase 2: Consolidation (post-remission therapy)

Once remission is achieved, further treatment is needed because small numbers of leukemia cells almost always remain even when standard tests look normal. Consolidation therapy aims to eliminate this residual disease and reduce the risk of relapse.

This phase may involve:

• Additional cycles of chemotherapy, often less intensive than induction but still requiring hospital stays or close monitoring.
• For higher-risk patients, an allogeneic stem cell transplant (see below) instead of or after further chemotherapy.
• For ALL, continued central nervous system treatment.

Phase 3: Maintenance (mainly in ALL)

For ALL, a longer maintenance phase follows, usually for two to three years. Maintenance involves lower-dose oral and injected chemotherapy taken at home, with regular clinic visits. Maintenance is generally not used in AML, with the exception of certain subtypes and newer oral drugs.

Targeted therapy

Many newer drugs target specific genetic changes in leukemia cells. These include:

• FLT3 inhibitors (such as midostaurin) for FLT3-mutated AML.
• IDH1 and IDH2 inhibitors for AML with those mutations.
• BCL-2 inhibitors (venetoclax), often combined with lower-intensity chemotherapy in older or less fit AML patients.
• Tyrosine kinase inhibitors (such as imatinib, dasatinib, ponatinib) for Philadelphia-chromosome-positive ALL.

Targeted drugs are usually given alongside chemotherapy rather than instead of it.

Immunotherapy

Immunotherapies use the body’s immune system, or laboratory-engineered immune cells, to attack leukemia. They are most established in B-cell ALL and include:

• Monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin, which target proteins on ALL cells.
• CAR T-cell therapy, in which a patient’s own T cells are collected, genetically modified to recognise leukemia cells, and infused back. CAR T-cell therapy is used in selected patients with relapsed or refractory B-cell ALL.

Availability of specific immunotherapies varies by centre and country.

Treatment of older or less fit patients

For older adults with AML, or those who cannot tolerate intensive chemotherapy, doctors often use lower-intensity regimens such as hypomethylating agents (azacitidine, decitabine) combined with venetoclax. These regimens can produce remissions with fewer side effects than traditional induction, although they may not cure the disease in the same way that intensive therapy plus transplant can.

Stem Cell Transplant (Bone Marrow Transplant)

For many patients with high-risk or relapsed acute leukemia, a stem cell transplant (also called a bone marrow transplant, or BMT) offers the best chance of long-term cure. It is a major undertaking and is not needed for every patient.

What a transplant does

A stem cell transplant replaces the patient’s diseased bone marrow with healthy blood-forming stem cells. Before the transplant, very high-dose chemotherapy (sometimes with radiation) is given — this is called conditioning. Conditioning destroys remaining leukemia cells and also clears space in the marrow. New stem cells are then infused into a vein, much like a blood transfusion. Over days to weeks, they travel to the marrow and begin producing healthy blood cells — a process called engraftment.

Types of transplant

• Allogeneic transplant uses stem cells from a donor — a matched sibling, a matched unrelated donor, a half-matched (haploidentical) family member, or umbilical cord blood. The donor’s immune cells also help fight any remaining leukemia, an effect called “graft-versus-leukemia.” This is the type usually used for acute leukemia.
• Autologous transplant uses the patient’s own stem cells, collected and stored before high-dose chemotherapy. It is rarely used for acute leukemia, but may have a role in selected situations.

The transplant process, step by step

1. Pre-transplant evaluation — detailed assessment of heart, lung, liver, and kidney function, infection screening, dental review, and discussion of fertility preservation where relevant.
2. Donor search and matching — testing siblings and, if needed, searching unrelated donor registries.
3. Conditioning therapy — several days of high-dose chemotherapy, sometimes with total-body irradiation.
4. Stem cell infusion — the new stem cells are given through a central venous line.
5. Engraftment phase — usually two to four weeks in a specialised unit, with very low blood counts and high infection risk.
6. Early recovery — close monitoring as the new immune system rebuilds, typically over months.
7. Long-term follow-up — for years, focused on watching for relapse, graft-versus-host disease, and late effects.

Whether a transplant is the right step depends on the leukemia’s risk category, response to initial treatment, donor availability, age, and overall health. This is one of the most important conversations to have with your hematology and transplant team.

Side Effects and How They Are Managed

Treatment for acute leukemia is demanding, but most side effects are expected and can be managed. Common ones include:

• Low blood counts — almost universal during treatment, leading to fatigue, infection risk, and bleeding risk. Managed with transfusions, growth factor injections, and protective isolation when counts are very low.
• Infections — the most serious short-term risk. Fever during low counts is treated as an emergency with broad-spectrum antibiotics. Preventive antibiotics, antivirals, and antifungals are often used.
• Nausea, vomiting, and loss of appetite — modern anti-sickness medications have made this much more controllable than in the past.
• Mouth sores (mucositis) — common with intensive chemotherapy and conditioning regimens; managed with mouth care and pain relief.
• Hair loss — expected with intensive chemotherapy. It usually grows back.
• Liver, kidney, and heart effects — monitored with regular blood tests and scans.
• Tumour lysis syndrome — a rapid breakdown of leukemia cells at the start of treatment that can affect kidneys and electrolytes. Prevented with fluids and specific medications.
• Graft-versus-host disease (GVHD) — after allogeneic transplant, donor immune cells may attack the patient’s skin, gut, liver, or other organs. GVHD can be acute or chronic and is treated with immunosuppressive drugs.
• Fertility effects — intensive chemotherapy and especially transplant conditioning can affect fertility. Where time allows, fertility preservation is usually discussed before treatment begins.

A dedicated team of hematologists, transplant physicians, nurses, dietitians, and sometimes psychologists works to anticipate and manage these side effects throughout treatment.

Monitoring and Response Assessment

Throughout treatment, doctors monitor how well the leukemia is responding. This includes:

• Regular blood counts to track recovery and look for abnormalities.
• Repeat bone marrow tests to confirm remission and check for residual disease.
• Measurable (minimal) residual disease (MRD) testing — highly sensitive tests that can detect very small numbers of leukemia cells. MRD results increasingly guide whether to escalate treatment or consider transplant, particularly in ALL and certain AML subtypes.
• Repeat genetic and molecular tests at key points.

Achieving and staying in remission is the central goal, and these tests are how that progress is tracked.

Lifestyle and Self-Management During Treatment

While treatment is medically led, day-to-day choices can support your body and reduce risks. Your team will give you specific instructions, but general patterns include:

• Infection prevention — careful hand hygiene, avoiding crowded places when blood counts are low, staying away from people who are ill, and following food safety guidance (avoiding raw or undercooked foods, unwashed produce, and unpasteurised dairy).
• Nutrition — eating enough protein and calories to support healing, even when appetite is poor. A dietitian is often part of the care team.
• Rest balanced with gentle activity — short walks and light movement, where allowed, can help with energy, mood, and circulation.
• Mouth and skin care — following specific protocols to prevent infection and reduce mucositis.
• Avoiding smoking and alcohol — both add stress to organs already under pressure.
• Emotional support — counselling, peer support groups, and talking openly with family and the care team are all important parts of getting through treatment.

Complications and Long-Term Effects

Some complications appear during treatment; others may appear months or years later. Long-term considerations after acute leukemia treatment can include:

• Relapse — the leukemia returning. The risk is highest in the first two years and declines over time. Surveillance bone marrow tests are part of follow-up.
• Chronic GVHD after allogeneic transplant, which can affect skin, mouth, eyes, lungs, gut, and joints.
• Late infections — the immune system takes time to rebuild fully after transplant, sometimes a year or more.
• Heart and lung effects from certain chemotherapy drugs or radiation.
• Endocrine effects — thyroid problems, reduced bone density, and changes in fertility or hormone production.
• Secondary cancers — a small long-term risk after some chemotherapy and radiation regimens.
• Fatigue and cognitive changes — persistent tiredness and difficulties with concentration or memory (“chemo brain”), which often improve but may take time.
• Emotional and psychological effects — anxiety, depression, and post-treatment adjustment difficulties are common and treatable.

Structured long-term follow-up is designed to find and treat these issues early.

Living with Acute Leukemia

Acute leukemia is unusual among cancers because treatment is so concentrated in the first months, and then life shifts into a longer phase of recovery and follow-up. People often describe this transition as harder than expected: the intense activity of treatment ends, and the slower work of rebuilding begins.

Useful things to know about this phase:

• Energy returns gradually. Most people feel substantially better six months to a year after intensive treatment ends, but full recovery, especially after transplant, can take longer.
• Going back to work or school is usually possible, often part-time at first. Your team can guide timing based on blood counts and immune recovery.
• Vaccinations need to be re-planned, particularly after transplant. Your team will provide a schedule for re-vaccination.
• Mental health deserves the same attention as physical health. Many treatment centres include psychologists or counsellors as part of follow-up.
• Family and relationships are affected too. Open conversations and, where helpful, family counselling can ease the adjustment.
• Fertility and family planning can be revisited with specialists after treatment, depending on what was done before.

Many patients are eventually able to return to work, hobbies, sport, travel, and the rhythms of ordinary life, sometimes with new perspective on what matters to them.

Acute Leukemia in Children

Acute leukemia is the most common cancer in children, and childhood leukemia — particularly ALL — is one of the success stories of modern oncology. With current treatment, a high proportion of children with ALL are cured.

Differences in childhood acute leukemia

• ALL is much more common in children than AML. The treatment, response, and outlook for childhood ALL are generally better than for adult ALL.
• Treatment is intensive but long. A typical childhood ALL regimen includes induction, consolidation, central nervous system prophylaxis, and a maintenance phase of about two to three years.
• Pediatric protocols are highly standardised. Many centres treat children on cooperative-group protocols, which has driven steady improvements in outcomes.
• Side-effect management is tailored to children, with attention to growth, schooling, nutrition, and emotional development.
• Late effects — including on growth, learning, fertility, heart, and bone health — are followed for many years through specialised survivorship clinics.

Supporting a child through treatment

For parents, much of the work is practical and emotional: helping the child understand what is happening in age-appropriate language, maintaining as much normal routine as possible, supporting siblings, and coordinating with school. Child-life specialists, paediatric oncology nurses, and counsellors are central to most paediatric units and can be a great help.

For paediatric AML and high-risk ALL, stem cell transplant may be part of the plan. Decisions are made by paediatric hematology and transplant teams in close discussion with the family.

Preventing Complications and Watching for Relapse

There is no proven way to prevent acute leukemia, because the biological causes are not fully understood. Once treatment is complete, however, several things help reduce the risk of complications and catch problems early:

• Attending all follow-up appointments, including bone marrow tests when scheduled.
• Reporting new symptoms promptly — particularly fever, new bruising, unexplained pain, or returning fatigue.
• Following the re-vaccination schedule after transplant.
• Staying engaged with any specialty clinics (cardiology, endocrinology, dermatology) where late effects are being monitored.
• Avoiding smoking and limiting alcohol, both of which add to long-term risk.
• Maintaining a balanced diet, gentle exercise as tolerated, and sleep.

When to Seek Urgent Care

During and after treatment, certain symptoms need urgent medical attention, often the same day. These include:

• Fever, especially above 38°C (100.4°F), or chills, particularly if your blood counts are low.
• Severe or worsening bleeding — nosebleeds that will not stop, bleeding gums, blood in urine or stool, or unusual bruising.
• Severe shortness of breath, chest pain, or rapid heartbeat.
• Severe headache, confusion, seizures, or sudden weakness.
• Severe abdominal pain or persistent vomiting.
• Signs of infection at a central line site — redness, swelling, pain, or discharge.

Most treatment centres provide a 24-hour contact number for patients in active treatment or recent follow-up. It is sensible to keep this number easily accessible.

Frequently Asked Questions

Is acute leukemia curable?

Many patients with acute leukemia achieve remission, and a significant number are cured, particularly children with ALL and adults with certain favourable AML subtypes. Outcomes depend on the specific subtype, genetic features, age, response to initial treatment, and whether transplant is part of the plan. Your hematologist can give a personalised picture once all the diagnostic tests are complete.

How long does treatment take?

For AML, intensive treatment (induction plus consolidation) usually spans about six to nine months, sometimes followed by transplant. For ALL, treatment is longer because of the maintenance phase — typically two to three years in total, with the most intensive parts at the beginning.

Will I need a stem cell transplant?

Not everyone does. Transplant is generally considered for patients with higher-risk disease, those who do not achieve a deep remission, or those who relapse. Risk is determined by genetic features and response to initial therapy. This is one of the most important conversations to have early with your team.

Can I be treated as an outpatient?

Induction therapy almost always requires extended hospital stays. Some consolidation cycles, maintenance therapy, and certain lower-intensity regimens can be given partly or fully as outpatient care, depending on the centre and the regimen. Transplant requires a long inpatient stay followed by close outpatient monitoring.

What is “remission” and does it mean I am cured?

Remission means leukemia cells are no longer detectable by standard tests and blood counts have recovered. It is a major milestone but not the same as cure. Small numbers of leukemia cells may still remain, which is why consolidation and, in some cases, transplant are needed. Long-term remission over several years is what is generally considered cure.

Can acute leukemia be inherited?

Most cases are not inherited. A small number occur in families with specific genetic syndromes. If there is a strong family history of leukemia or related cancers, your team may recommend genetic counselling.

What about fertility?

Intensive chemotherapy and especially transplant conditioning can affect fertility. Where time allows, options such as sperm banking, egg or embryo freezing, and ovarian tissue preservation are usually discussed before treatment starts. After treatment, a specialist can review fertility status and family-planning options.

Can I travel or be active during treatment?

Activity is encouraged within the limits set by your blood counts and energy. Travel, especially air travel, is usually restricted during intensive phases because of infection risk and the need to stay close to the treatment centre. Your team can advise on what is reasonable at each stage.

Conclusion

Acute leukemia is a serious and fast-moving illness, but it is also one in which outcomes have improved substantially because of better classification, more targeted drugs, refined chemotherapy regimens, advances in stem cell transplantation, and stronger supportive care. The path is demanding, often months of intensive treatment followed by longer recovery, but it is a path many patients walk — and complete — with good results.

Understanding your specific type and risk group, knowing what each phase of treatment is for, and staying engaged in follow-up after remission are the most useful things a patient or family can do. The rest is the work of your hematology team, who will tailor each step to your situation.